Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“I find MedCity News a great resource for taking the pulse of the market and sourcing potential investment opportunities.”

Bernie Rudnick, Angel investor and advisor, CapGenic Advisors, LLC


Sign up for our daily newsletter


Belgium’s biotech tests new class of antibiotics to treat resistant infections

November 26, 2012 2:11 am by | 0 Comments

BRUSSELS (Reuters) - Belgian biotechnology group Galapagos is testing a new class of antibiotics that could be used to treat bacterial infections that have become resistant to other forms of medication.

The group said on Monday that in laboratory tests its new candidate drug, CAM 1, showed better results than traditional antibiotics against the bacteria causing MRSA, a life threatening disease sometimes contracted by hospital patients.

Galapagos said it hoped to enter clinical tests for the drug, which it fully owned, in 2014.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
0 comments